About KemPharm (NASDAQ:KMPH)
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($3.28) per share
Price / Book-1.16
Return on EquityN/A
Return on Assets-53.56%
Frequently Asked Questions for KemPharm (NASDAQ:KMPH)
What is KemPharm's stock symbol?
KemPharm trades on the NASDAQ under the ticker symbol "KMPH."
How were KemPharm's earnings last quarter?
KemPharm, Inc. (NASDAQ:KMPH) posted its earnings results on Wednesday, May, 10th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.21. View KemPharm's Earnings History.
Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?
4 brokers have issued twelve-month price objectives for KemPharm's shares. Their forecasts range from $7.00 to $13.00. On average, they expect KemPharm's share price to reach $9.00 in the next year. View Analyst Ratings for KemPharm.
What are Wall Street analysts saying about KemPharm stock?
Here are some recent quotes from research analysts about KemPharm stock:
- 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (11/16/2017)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 10, 2017, 16:01 ET Date and time of production: August 10, 2017, 16:01 ET Target Price / Valuation Methodology: KemPharm – KMPH Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $7/share for KMPH, assuming a stable timeline for KemPharm’s lead products, KP415, KP201/IR and KP511/ER. Additionally, we assume a KP415 launch in 2020 and KP201/IR and KP511/ER launches in 2021. Our valuation assumes a generic launch against KP201/IR around 2031 and generic launches against KP415 and KP511/ER around 2032. This corresponds with the expiries of composition of matter patents, before any FDA term extensions, for all three products." (8/10/2017)
Who are some of KemPharm's key competitors?
Some companies that are related to KemPharm include AcelRx Pharmaceuticals (ACRX), Zafgen (ZFGN), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), ProQR Therapeutics N.V. (PRQR), Affimed N.V. (AFMD), Verona Pharma Plc (VRP), Synthetic Biologics (SYN), Motif Bio plc (MTFB), Viking Therapeutics (VKTX), Nexvet Biopharma plc (NVET), MEI Pharma (MEIP), Lipocine (LPCN), ADMA Biologics (ADMA), Flex Pharma (FLKS), Aeglea BioTherapeutics (AGLE), Ergomed PLC (ERGO) and Applied Genetic Technologies Corporation (AGTC).
Who are KemPharm's key executives?
KemPharm's management team includes the folowing people:
- Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 42)
- Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller (Age 33)
- Gordon K. Johnson, Chief Business Officer
When did KemPharm IPO?
(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
Who owns KemPharm stock?
KemPharm's stock is owned by a number of of institutional and retail investors. Top institutional investors include
DELAWARE STREET CAPITAL MASTER FUND, L.P.
(10.00%), Alyeska Investment Group L.P. (6.77%) and C WorldWide Group Holding A S (2.97%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.
Who bought KemPharm stock? Who is buying KemPharm stock?
KemPharm's stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S and Alyeska Investment Group L.P.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.
How do I buy KemPharm stock?
Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KemPharm's stock price today?
One share of KemPharm stock can currently be purchased for approximately $3.80.
How big of a company is KemPharm?
KemPharm has a market capitalization of $54.23 million. The specialty pharmaceutical company earns $-16,510,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. KemPharm employs 32 workers across the globe.
How can I contact KemPharm?
KemPharm's mailing address is 2500 Crosspark Rd Ste E126, CORALVILLE, IA 52241-4710, United States. The specialty pharmaceutical company can be reached via phone at +1-319-6652575 or via email at [email protected]
MarketBeat Community Rating for KemPharm (KMPH)MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for KemPharm (NASDAQ:KMPH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$9.00 (136.84% upside)|
Consensus Price Target History for KemPharm (NASDAQ:KMPH)
Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/11/2017||Canaccord Genuity||Reiterated Rating||Buy||$7.00||High|
|8/10/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$13.00||Medium|
|6/28/2017||Roth Capital||Initiated Coverage||Buy -> Buy||$8.00||High|
|5/15/2017||Royal Bank Of Canada||Reiterated Rating||Buy||$8.00||Medium|
Earnings History and Estimates Chart for KemPharm (NASDAQ:KMPH)
Earnings History by Quarter for KemPharm (NASDAQ KMPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for KemPharm (NASDAQ KMPH)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 38.29%
Insider Trades by Quarter for KemPharm (NASDAQ KMPH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/25/2017||R. Laduane Clifton||CFO||Buy||300||$3.78||$1,134.00|| |
|9/14/2017||Delaware Street Capital Master||Major Shareholder||Buy||325,888||$3.27||$1,065,653.76|| |
|8/24/2017||Daniel L Cohen||EVP||Buy||5,000||$2.58||$12,900.00|| |
|8/24/2017||Gordon K Johnson||Insider||Buy||4,000||$2.60||$10,400.00|| |
|6/20/2017||Travis C Mickle||CEO||Buy||8,000||$3.45||$27,600.00|| |
|6/19/2017||R. Laduane Clifton||CFO||Buy||275||$3.30||$907.50|| |
|5/25/2017||Daniel L Cohen||EVP||Buy||2,500||$4.11||$10,275.00|| |
|3/31/2017||Daniel L Cohen||EVP||Buy||2,500||$4.48||$11,200.00|| |
|3/24/2017||R. Laduane Clifton||CFO||Buy||1,000||$4.24||$4,240.00|| |
|3/22/2017||Travis C Mickle||CEO||Buy||2,000||$4.10||$8,200.00|| |
|3/20/2017||David S Tierney||Director||Buy||1,000||$4.20||$4,200.00|| |
|11/30/2016||Daniel L Cohen||EVP||Buy||5,000||$3.50||$17,500.00|| |
|9/6/2016||Daniel L Cohen||EVP||Buy||10,000||$4.75||$47,500.00|| |
|8/17/2016||Travis C Mickle||CEO||Buy||5,000||$4.95||$24,750.00|| |
|3/29/2016||Travis C Mickle||CEO||Buy||2,450||$14.57||$35,696.50|| |
Latest Headlines for KemPharm (NASDAQ KMPH)
|KemPharm, Inc. (KMPH) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - November 19 at 10:00 AM
|KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA|
finance.yahoo.com - November 17 at 11:26 AM
|KemPharma reports 3Q loss|
www.cnbc.com - November 11 at 3:17 PM
|How Much is KemPharm Inc’s (KMPH) CEO Getting Paid?|
finance.yahoo.com - November 11 at 3:17 PM
|KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update|
finance.yahoo.com - November 11 at 3:17 PM
|KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511|
finance.yahoo.com - November 7 at 6:17 AM
|KemPharm, Inc. (KMPH) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - November 5 at 1:52 AM
|-$0.69 Earnings Per Share Expected for KemPharm, Inc. (KMPH) This Quarter|
www.americanbankingnews.com - November 4 at 9:26 PM
|KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies|
finance.yahoo.com - November 3 at 12:53 PM
|KemPharm, Inc. to Report Third Quarter 2017 Results|
finance.yahoo.com - November 2 at 4:26 AM
|KemPharm, Inc. (KMPH) Scheduled to Post Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 8:36 AM
|KemPharm (KMPH) vs. Its Rivals Head-To-Head Survey|
www.americanbankingnews.com - October 30 at 5:26 PM
|KemPharm, Inc. (KMPH) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 11 at 2:50 AM
|Featured Company News - KemPharm Signs Technology Licensing Agreement with Genco to Develop Prodrug-Based Therapy for Pediatric Indications of Tourette’s syndrome with ADHD|
finance.yahoo.com - October 7 at 1:54 AM
|KemPharm (KMPH) and Genco Sciences Announce Pact to Develop Prodrug-Based Therapy for Rare Pediatric Indications of Tourette's Syndrome with ADHD|
www.streetinsider.com - October 5 at 7:16 AM
|KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD|
finance.yahoo.com - October 5 at 7:16 AM
| Brokerages Anticipate KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.69 Per Share|
www.americanbankingnews.com - September 27 at 4:30 PM
|KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate|
finance.yahoo.com - September 21 at 12:29 PM
|KemPharm, Inc. (KMPH) Earns Buy Rating from Canaccord Genuity|
www.americanbankingnews.com - September 17 at 10:22 PM
|KemPharm, Inc. (KMPH) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - September 16 at 3:10 AM
|KemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 Shares|
www.americanbankingnews.com - September 15 at 4:30 PM
|Astellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial Data|
www.rttnews.com - September 13 at 3:33 AM
|KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA|
finance.yahoo.com - September 13 at 3:33 AM
|KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference|
finance.yahoo.com - September 1 at 1:55 AM
|KemPharm, Inc. (KMPH) Insider Buys $10,400.00 in Stock|
www.americanbankingnews.com - August 25 at 8:54 PM
|KemPharm, Inc. (KMPH) EVP Daniel L. Cohen Buys 5,000 Shares|
www.americanbankingnews.com - August 25 at 8:54 PM
|KemPharm, Inc. (KMPH) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 22 at 2:58 AM
|KemPharm, Inc. (KMPH) Expected to Announce Earnings of -$0.69 Per Share|
www.americanbankingnews.com - August 21 at 6:14 AM
|KemPharm, Inc. (KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - August 13 at 6:32 PM
|KemPharm (KMPH) Announces Prelim. Results from KP415 Pharmacokinetic Single and Multiple Dose Trial|
www.streetinsider.com - August 12 at 1:54 AM
|KemPharma reports 2Q loss|
www.cnbc.com - August 12 at 1:54 AM
|KemPharm, Inc. (NASDAQ:KMPH) Issues Quarterly Earnings Results|
www.americanbankingnews.com - August 11 at 5:16 PM
|KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial|
finance.yahoo.com - August 11 at 5:49 AM
|KemPharm, Inc. Reports Second Quarter 2017 Results|
finance.yahoo.com - August 11 at 5:49 AM
|KemPharm's (NASDAQ:KMPH) "Buy" Rating Reaffirmed at Canaccord Genuity|
www.americanbankingnews.com - August 10 at 6:26 PM
|KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety|
finance.yahoo.com - August 8 at 7:59 PM
|KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference|
finance.yahoo.com - August 3 at 11:31 PM
|KemPharm, Inc. to Report Second Quarter 2017 Results|
finance.yahoo.com - August 2 at 2:46 AM
|KemPharm, Inc. (NASDAQ:KMPH) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 28 at 11:21 AM
|KemPharm, Inc. (KMPH) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - July 3 at 12:04 PM
|KemPharm, Inc. (KMPH) Now Covered by Roth Capital|
www.americanbankingnews.com - July 2 at 3:08 PM
|KemPharm (KMPH) Announced Two Advances Involving its Prodrug Development Pipeline to Treat ADHD|
www.streetinsider.com - June 30 at 12:52 AM
|KemPharm (KMPH) Granted First Patent for KP746|
www.streetinsider.com - June 26 at 8:05 PM
|KemPharma reports 1Q loss|
www.cnbc.com - May 10 at 6:06 PM
|KEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits|
biz.yahoo.com - March 28 at 5:46 PM
|KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting|
us.rd.yahoo.com - March 16 at 6:58 PM
|7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting|
us.rd.yahoo.com - March 16 at 6:58 PM
|KEMPHARM, INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 10 at 7:23 PM
|KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release)|
globenewswire.com - March 10 at 7:57 AM
|KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results|
us.rd.yahoo.com - March 9 at 9:06 PM
KemPharm (NASDAQ KMPH) Chart for Friday, November, 24, 2017